Reference is made to the stock exchange notice dated 21 December 2009 and the
prospectus dated 21 December 2009 regarding a subsequent offering of up to
8,000,000 offer shares in NorDiag ASA ("NorDiag" or the "Company"), each with a
nominal value of NOK 1.00, at a subscription price of NOK 1.00 per share with
subscription rights for shareholders of the Company as of 25 November 2009,
except shareholders who were invited to participate in the private placement
completed on 25 November 2009.
The subscription period in the subsequent offering in NorDiag expired at 17:30
(CET) on 12 January 2010. At the end of the subscription period, NorDiag had
received subscriptions for a total of 19,357,830 new shares. Consequently, the
subsequent offering was oversubscribed by approximately 142 per cent.
Approximately 71 per cent of the new shares offered (approximately 5.7 million
shares) were subscribed by exercising subscription rights. Approximately 171 per
cent of the new shares on offer (approximately 13.7 million shares) were
subscribed for through oversubscription by holders of subscription rights or by
subscribers without subscription rights.
In a board meeting 18 January 2010, the Board of Directors of NorDiag approved
the final allocation of the shares offered in the subsequent offering based on
the allocation criteria set out in the prospectus dated 21 December 2009. A
total of 8,000,000 new shares have been allocated. Approximately 5.7 million new
shares have been allocated to subscribers on the basis of exercised subscription
rights. Approximately 2.3 million new shares have been allocated to holders of
subscription rights on basis of oversubscription. No allocation has been made to
subscribers without subscription rights.
Letters of notification of new shares allocated and the corresponding
subscription amount to be paid by each subscriber are expected to be distributed
from the VPS on 19 January 2010. Payment for the allocated shares falls due on
21 January 2010 in accordance with the payment procedures described in the
prospectus.
The new shares may not be transferred or traded before they are fully paid and
the share capital increase pertaining to the subsequent offering has been
registered with the Norwegian Register of Business Enterprises. It is expected
that the share capital increase will be registered in the Norwegian Register of
Business Enterprises on or about 26 January 2010 and that the new shares will be
admitted to trading on the Oslo Stock Exchange on the same day.
Through the subsequent offering, NorDiag will receive proceeds of NOK 8,000,000
before the deduction of transaction costs. Following registration of the share
capital increase in the Norwegian Register of Business Enterprises, the
Company's share capital will be NOK 62,065,282 divided into 62,065,282 shares,
each with a nominal value of NOK 1.00.
DnB NOR Markets acted as manager in the subsequent offering.
Contact:
Contact: CEO Mårten Wigstøl Phone: +47 911 65775
CFO Tone Kvåle Phone: +47 915 19576
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing
automated solutions (instruments and tests) for sample preparation of DNA from
difficult biological samples. DNA diagnostics give more rapid and precise
answers, and is the fastest growing field within diagnostics. The company's
sample preparation solutions are today used in connection with STI,
tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large
and small laboratories. NorDiag was founded in 2003 and has its headquarters in
Oslo, Norway. The company has offices and laboratories in Stockholm, Sweden, in
West Chester (PA), USA and in Vienna, Austria. The group has today 40.1
man-labour years. NorDiag is listed on Oslo Stock Exchange with ticker NORD.
For further information, please see www.nordiag.com.
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
[HUG#1374402]
